期刊文献+

A high performance liquid chromatography method for the quantitative determination of ribavirin in human plasma and its application in a pharmacokinetics study 被引量:2

利巴韦林的含量测定以及人体药代动力学分析(英文)
原文传递
导出
摘要 The clinical pharmacokinetics of ribavirin after a single oral dose of 600 mg ribavirin tablets in healthy Chinese volunteers was studied. A rapid and simple high performance liquid chromatography (HPLC) method was developed to determine the ribavirin concentration in human plasma. C18 column was used for separation with a column temperature of 25℃, the mobile phase was ultrapure water adjusted to pH 3 with acetic acid at the flow rate of 1 mL/min, and the detection wavelength was set at 207 rim. The linear range of the standard curves was 50.4-2016.0 ng/mL and the lower limit of quantification (LLOQ) was 50.4 ng/mL. The relative recoveries of ribavirin were more than 90% in plasma. The RSD of the intra-day precision was less than 10% and that of inter-day was less than 15%. The pharmacokinetic parameters of ribavirin were calculated by WinNonlin. Results indicated that the two-compartment model was a better model for describing the pharmacokinetics profile of ribavirin than one-compartment model. The AUC0-t was 10807.8 h.ng/mL, the CL/F was 64879.5 mL, and the Cmax was 525.1 ng/mL. These results provided the experimental data for the development of ribavirin dosage form. 本文建立了简单、快速的HPLC方法测定利巴韦林在人血浆中的含量, 并研究了健康受试者体内利巴韦林片剂的药代动力学。HPLC方法选择C18色谱柱(250mm×4.6mm,5μm), 超纯水为流动相, 柱温为25°C, 检测波长为207nm。在50.4-2016.0ng/mL范围内线性关系良好(r=0.9998), 最低检测浓度为15ng/mL。低、中、高三个浓度的相对回收率大于90%, 日内精密度小于10%, 日间精密度小于15%。用药代动力学软件WinNonlin进行房室模型分析的结果显示:二室模型能更好地模拟利巴韦林在体内的过程。计算得到的AUC0-t、CL/F和Cmax分别是10807.8 h·ng/mL、64879.5 mL和525.1ng/mL。这些结果为药剂工作者开发利用利巴韦林剂型提供了参考。
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2013年第4期361-364,共4页 中国药学(英文版)
关键词 RIBAVIRIN HPLC PHARMACOKINETICS Compartmental model 利巴韦林 高效液相色谱法 药代动力学 房室模型
  • 相关文献

参考文献7

  • 1Jindrich, C.Jr.; Martin, M.; Gerold, H. Antiviral Res. 2005, 66, 81-97. 被引量:1
  • 2Bosch, M.E.; S-nchez, A.J.R.; Rojas, ES.; Ojeda, C.B.J. Pharm. Biomed. Anal. 2007, 45, 185-193. 被引量:1
  • 3Sun, A.X.; Qin, J.J. Chin. J. Clin. Pharm. 2006, 15, 14-17. 被引量:1
  • 4Zhao, L.; Wen, A.D.; Yang, Z.F. Pharm. J. Chin. PLA. 2005, 21, 277-280. 被引量:1
  • 5Gao, N.; Guo, Y.Z.; Qiao, H.L.; Jia, L.J.; Zhang, L.R.; Zhang, Q.T.; Tian, X. Chin. J. Clin. Pharmacol. Ther 2005, 10, 462-465. 被引量:1
  • 6Shou, W.Z.; Bu, H.Z.; Addison, T.; Jiang, X.Y.; Weng, N.D. J. Pharm. Biomed. Anal. 2002, 29, 83-94. 被引量:1
  • 7Zhou, Z.L.; Yu, X.Y.; Yang, M.; Peng, H.Y.; Chen, T.F.; Lin, Q.X.; Shah, Z.X.; Liu, X.Y.; Deng, C.Y.; Zhu, P.; Huang, X.Z.; Lin, S.G. Biomed. Chromatogr. 2008, 22, 1409-1415. 被引量:1

同被引文献27

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部